Mustang Bio Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights Nov 12, 2021
Mustang Bio Announces Exclusive Worldwide License Agreement with Leiden University Medical Centre for Clinical-Stage Lentiviral Gene Therapy with Curative Potential for RAG1 Severe Combined Immunodeficiency Nov 10, 2021
Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at 63rd American Society of Hematology (ASH) Annual Meeting Nov 04, 2021
Mustang Bio Awarded NIH Grant For MB-106 CD20-Targeted CAR T Cell Therapy for Treatment of B-cell non-Hodgkin Lymphomas Nov 01, 2021
Avenue Therapeutics Receives Interim Response to its Formal Dispute Resolution Request from U.S. Food and Drug Administration Office of New Drugs Oct 25, 2021
Fortress Biotech to Participate in Dawson James Securities’ 6th Annual Small Cap Growth Conference Oct 18, 2021
